scholarly journals The Kinetics of Anti-HLA Antibodies in the First Year after Kidney Transplantation: In Whom and When Should They Be Monitored?

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Maria Cristina Ribeiro de Castro ◽  
Erick A. Barbosa ◽  
Renata P. Souza ◽  
Fabiana Agena ◽  
Patrícia S. de Souza ◽  
...  
Keyword(s):  
Acute Rejection ◽  
De Novo ◽  
First Year ◽  
Sharp Drop ◽  
Hla Antibodies ◽  
Single Antigen ◽  
The Impact ◽  
Kinetics Of ◽  
Time Point ◽  
Rejection Rates

The impact of the kinetics of the anti-HLA antibodies after KTx on the occurrence of acute rejection as well as the better time-point to monitor anti-HLA Abs after transplantation is not completely defined. This prospective study followed 150 patients over 12 months after transplantation. Serum IgG anti-HLA Abs were detected by single antigen beads after typing donors and recipients for loci A, B, C, DR, and DQ. Before KTx, 89 patients did not present anti-HLA Abs and 2% developed “de novo” Abs during the 1st year, 39 patients were sensitized without DSAs, and 13% developed DSA after surgery; all of them presented ABMR. Sensitized patients presented higher acute rejection rates (36.4% versus 13.5%, p<0.001), although 60% of the patients did not present ABMR. Patients, in whom DSA-MFI decreased during the first two weeks after surgery, did not develop ABMR. Those who sustained their levels presented a rate of 22% of ABMR. 85% of patients developed ABMR when MFIs increased early after transplantation (which occurred in 30% of the DSA positive patients). In the ABMR group, we observed an iDSA-MFI sharp drop on the fourth day and then an increase between the 7th and 14th POD, which suggests DSA should be monitored at this moment in sensitized patients for better ABMR prediction.

The Kinetics of HLA Antibodies After Kidney Transplantation - the Impact On Acute Rejection and Graft Loss.

2014 ◽  
Vol 98 ◽  
pp. 512
Author(s):  
E. Barbosa ◽  
R. Souza ◽  
F. Agena ◽  
G. Maciel ◽  
N. Panajotopoulos ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Acute Rejection ◽  
Graft Loss ◽  
Hla Antibodies ◽  
The Impact ◽  
Kinetics Of

De novo anti-HLA antibodies have the highest incidence in the first year after transplantation

2003 ◽  
Vol 64 (10) ◽  
pp. S31 ◽  
Author(s):  
Alin Girnita ◽  
Rene Duquesnoy ◽  
Anthony Demetris ◽  
Carol Bentlejewski ◽  
David Guaspari ◽  
...  
Keyword(s):  
De Novo ◽  
First Year ◽  
Hla Antibodies

A Three Center Study Reveals New Insights into the Impact of Non-HLA Antibodies on the Acute Rejection Process in Lung Transplantation

2015 ◽  
Vol 34 (4) ◽  
pp. S119-S120 ◽  
Author(s):  
N.L. Reinsmoen ◽  
J. Mirocha ◽  
C. Ensor ◽  
M. Marrari ◽  
G.E. Chaux ◽  
...  
Keyword(s):  
Acute Rejection ◽  
Lung Transplantation ◽  
Hla Antibodies ◽  
The Impact ◽  
Center Study

scholarly journals Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Isabel Pérez-Flores ◽  
Jose Luis Santiago ◽  
Natividad Calvo-Romero ◽  
Alberto Barrientos-Guzmán ◽  
Ana Isabel Sánchez-Fructuoso
Keyword(s):  
Graft Survival ◽  
Negative Impact ◽  
First Year ◽  
Hla Antibodies ◽  
Positive Predicted Value ◽  
Antigen Assay ◽  
Single Antigen ◽  
One Year ◽  
The One ◽  
Cellular Rejection

It is well know that anti-HLA antibodies are an important obstacle in kidney transplantation. Our aim was to study the clinical impact of pretransplant donor specific anti-HLA antibodies (HLA-DSA), in highly sensitized (HS) patients. We analyzed retrospectively the day-of-transplant sera by Luminex Single Antigen Assay (LSA) in HS patients, and the results were correlated with episodes of humoral and cellular rejection as well as with graft and patient survival. All HS subjects received the same induction therapy and rejection episodes were biopsy proven. Thirteen patients (56.5%) preformed HLA-DSA, and we observed higher incidence of acute rejection in aforementioned patients than in the pre-transplant negatives DSA recipients (77% versus 30%, ). The one-year graft survival was significantly reduced in positive pre-transplant HLA-DSA patients (60% versus 100%, Breslow). The positive predicted value of HLA-DSA in relation to rejection reached 100% if patients lost their previous graft in the first year after transplant. Among anti-HLA antibodies present in patients before transplant, HLA-DSA were significantly associated with high risk of acute humoral and cellular rejection and reduced graft survival in posttransplant outcome. The negative impact of these antibodies was even higher when patients suffered an early loss of the previous transplant.

Negative Regulation of Cell Cycle Kinetics of Human Hematopoietic Cells by the Transcription Factor Dmtf1.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3359-3359
Author(s):  
Michihiro Kobayashi ◽  
Edward F. Srour
Keyword(s):  
Cell Cycle ◽  
Transcription Factor ◽  
Cord Blood ◽  
Hematopoietic Cells ◽  
Dominant Negative ◽  
Cell Cycle Kinetics ◽  
Cd34 Cells ◽  
The Impact ◽  
Kinetics Of ◽  
Time Point

Abstract Hematopoietic stem cells (HSCs) are predominantly quiescent with only a small number entering active phases of cell cycle at any time point. With such tightly regulated cell cycle kinetics, HSCs ensure preservation of the stem cell pool. Many cell cycle-related proteins, mainly tumor suppressor genes, are involved in maintenance of HSCs quiescence. Dmtf1 (Cyclin D-binding Myb-like Protein1) is a transcription factor that negatively regulates cell cycle by inducing Arf expression, and its deletion has been reported in some leukemias (Bodner SM et al, 1999). As there is no information regarding the role of Dmtf1 in hematopoiesis, we examined the impact of Dmtf1 on regulating cell cycle kinetics of hematopoietic progenitor cells. Dmtf1 mRNA was expressed in human granulocytes, lymphocytes, CD34+ cells, and in murine Sca1+lin-CD117+ (KSL) cells. Using retroviral vectors (MIEG3/IRES-GFP), we first investigated cell cycle progression in 293 cells transduced with four different constructs; GFP only control vector (−), wild type Dmtf1 (WT), and two dominant negative mutants expressing a point mutation (K319E) or a deleted myb-like repeat box (dMHR). A total of 36.0% of sorted and cultured GFP+ control (−) cells were in S/G2+M 24hr after initiation of culture. Whereas 30.8% of cells expressing (WT) were in S/G2+M at the same time point, expression of the two dominant negative mutants K319E and dMHR induced 46.6% and 45.5% of the cells into S/G2+M, respectively suggesting that loss of Dmtf1 activity results in rapid cell proliferation. Interestingly, a 2.5-fold increase in the ecxpression of Arf and p21 mesured by qPCR was detected in cells transduced with WT only whereas other transduced cells did not show any change in expression of both Arf and p21. The impact of these constructs was then evaluated in cord blood cells using CFU assays. Cord blood CD34+ cells were transduced with the four vectors mentioned above and GFP+ cells were subsequently sorted and cultured. Both K319E and dMHR induced a 25% increase in the number of clonogenic progenitors relative to (−) while a modest decrease of 10% in colony numbers was detected in the WT group. Cells cycle analysis of these cells is currently under investigation. These results demonstrate that Dmtf1 acts as a negative regulator of cell cycle control in hematopoietic cells and suggests that it may play a role in the maintenance of HSC quiescence.

Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing

2015 ◽  
Vol 99 (9) ◽  
pp. 1976-1980 ◽  
Author(s):  
Caner Süsal ◽  
Daniel Wettstein ◽  
Bernd Döhler ◽  
Christian Morath ◽  
Andrea Ruhenstroth ◽  
...  
Keyword(s):  
De Novo ◽  
Graft Loss ◽  
Kidney Graft ◽  
Hla Antibodies ◽  
Single Antigen ◽  
Antigen Testing

The Impact of De Novo Donor Specific Anti-HLA Antibodies on the 5-Year Renal Transplant Outcome

2012 ◽  
Vol 94 (10S) ◽  
pp. 1051
Author(s):  
M. Banasik ◽  
M. Boratynska ◽  
K. Koscielska-Kasprzak ◽  
M. Zabinska ◽  
P. Chudoba ◽  
...  
Keyword(s):  
Renal Transplant ◽  
De Novo ◽  
Hla Antibodies ◽  
Transplant Outcome ◽  
The Impact

scholarly journals Abdominal Wall Transplantation: Indications and Outcomes

2020 ◽  
Vol 7 (4) ◽  
pp. 279-290
Author(s):  
Calum Honeyman ◽  
Roisin Dolan ◽  
Helen Stark ◽  
Charles Anton Fries ◽  
Srikanth Reddy ◽  
...  
Keyword(s):  
Abdominal Wall ◽  
De Novo ◽  
First Year ◽  
Published Data ◽  
Full Thickness ◽  
Transplant Recipients ◽  
Long Term Outcomes ◽  
Intestinal Transplant ◽  
Rejection Rates

Abstract Purpose of Review This article aims to review published outcomes associated with full-thickness vascularized abdominal wall transplantation, with particular emphasis on advances in the field in the last 3 years. Recent Findings Forty-six full-thickness vascularized abdominal wall transplants have been performed in 44 patients worldwide. Approximately 35% of abdominal wall transplant recipients will experience at least one episode of acute rejection in the first year after transplant, compared with rejection rates of 87.8% and 72.7% for hand and face transplant respectively. Recent evidence suggests that combining a skin containing abdominal wall transplant with an intestinal transplant does not appear to increase sensitization or de novo donor-specific antibody formation. Summary Published data suggests that abdominal wall transplantation is an effective safe solution to achieve primary closure of the abdomen after intestinal or multivisceral transplant. However, better data is needed to confirm observations made and to determine long-term outcomes, requiring standardized data collection and reporting and collaboration between the small number of active transplant centres around the world.

Sign in / Sign up

Export Citation Format

Share Document